Title: Meta-analysis on safety of standard vs prolonged infusion of beta-lactams

Running Title: Safety of prolonged infusion beta-lactams

Authors: Hunter Rolain[1], Zachary Schwartz[1], Raymond Jubriail[2], Kevin Downes[5,6], Lisa Hong[7], Alireza Fakhri Ravari[7], Nathaniel J. Rhodes,[2,3,4] Marc H. Scheetz[2-4]*

Affiliations:

[1] Midwestern University- Downers Grove Campus, Chicago College of Osteopathic Medicine, Downers Grove, IL, USA;

[2] Midwestern University- Downers Grove Campus, Department of Pharmacy Practice, Downers Grove, IL, USA;

[3] Midwestern University- Downers Grove Campus, Pharmacometrics Center of Excellence, Downers Grove, IL, USA;

[4] Northwestern Memorial Hospital, Department of Pharmacy, Chicago, IL, USA;

[5] Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA;

[6] Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA;

[7] Loma Linda University School of Pharmacy, Department of Pharmacy Practice, Loma Linda, CA, USA

*** Corresponding author and reprint requests:** Marc H. Scheetz, PharmD, MSc; Professor of Pharmacy Practice and Pharmacology; Midwestern University; 555 31st St., Downers Grove, IL 60515, Phone: 630-515-6116; Fax: 630-515-6958; Email: mschee@midwestern.edu

Word count: 2020 **Abstract word count: 272**

Abstract:

Background: Efficacy for prolonged infusion beta-lactam dosing schemes has been previously described, but there has been less focus on the safety of standard vs prolonged infusion protocols of beta-lactams. This study explored differences in adverse drug reactions (ADRs) reported for beta-lactams between each of these infusion protocols.

Methods: A systematic review of MEDLINE literature databases via PubMed was conducted and references were compiled. Articles were compiled and assessed with specific inclusion/exclusion criteria. We included randomized and nonrandomized, prospective, and retrospective cohort studies that reported adverse effects due to either standard (30-60 mins) or prolonged (≥3 hours) infusions of beta-lactam infusions. Total ADRs between strategies were analyzed by infusion methodology. The most consistently reported ADRs were subject to meta-analysis across studies.

Results: 13 studies met inclusion/exclusion criteria with data for 4184 patients. There was insufficient data to systematically analyze neurotoxicity or cytopenias. Eight studies reported on nephrotoxicity outcomes with no significant difference in event rates between standard (n=440/2117, 20.8%) vs prolonged infusion (n=264/1284, 20.6%) of beta-lactams (OR=1.09, 95% CI [0.91, 1.30]). Six studies reported on rates of diarrhea with no significant difference in event rates between standard (n=21/359, 5.8%) vs prolonged infusion (n=25/330, 7.6%) of beta-lactams (OR=1.33, 95% CI [0.71,2.47).

Conclusion: Prolonged and standard infusion schemes for beta-lactams demonstrated adverse effects at similar rates for both infusion schemes. Future research should focus on improved standardization of adverse effect definitions and a priori aim to study neurotoxicity and cytopenias. Consistent recording of ADRs and standardized definitions of these reactions will be paramount to further study of this subject.

Keywords: standard infusion; prolonged infusion; renal failure; beta-lactams; kidney damage, neurotoxicity, kidney injury, cefepime, piperacillin, ceftriaxone

Background:

Beta-lactams are among the most frequently utilized antibiotics worldwide [1,2] as they are first line options for multiple infectious syndromes [1-4]. Among the high use beta-lactam antibiotics are broad-spectrum cephalosporins such as cefepime, penicillin-beta-lactamase inhibitor combinations such as piperacillin-tazobactam, and carbapenems such as meropenem. Most often, beta-lactams are delivered as intermittent infusions (IIs) over a period of time ranging from 30 to 60 minutes (i.e., standard infusion (SI)), typically as a 30-minute infusion [5]. Because bacterial killing is improved when time over bacterial minimum inhibitory concentrations (MICs) is optimized, beta-lactams are increasingly being utilized in prolonged infusion platforms to improve efficacy [1-4, 6-17]. Prolonged infusions (PI) consist of extended infusions (EIs) that are longer than standard infusions (e.g., 3-4 hours) and continuous infusions (CI) that deliver constant concentrations of antibiotics without plans to stop. In this study, we classified both EI and CI as PI.

The efficacy of prolonged infusions has been shown to be either improved or equal to standard infusions [5,18-20,21]. Safety, however, has been less well explored. As with many drugs, ADRs for beta-lactams do occur, albeit infrequently, and are usually mild to moderate in severity. ADRs driven by dose and exposure are of particular interest to clinicians when a biologic relationship is identified, as they can be predicted and avoided. One such example of dose-dependent toxicity in beta-lactams is neurotoxicity [22,23]. Nephrotoxicity, on the other hand, is generally thought to be dose-independent and related to allergic-mediated mechanisms and type-II hypersensitivity reactions [22]. Although dose-toxicity relationships are reasonably established, the time course in which the dose is delivered has been less studied. When beta-lactams are given as standard infusions, higher serum and tissue peak concentrations are obtained while troughs are lower. In contrast, when prolonged infusions are utilized, peaks are lower while trough levels are higher. In both of these infusion types, for a fixed dose, the area under the curve (AUC, or total exposure) is the same. It is unknown if differences in pharmacokinetic parameters (e.g., different Cmax yet similar AUC) lead to differences in ADRs. Because there are few large and purpose-defined trials comparing the safety of standard versus prolonged infusion methods for the assessment of safety, we performed a systematic review to identify studies that documented rates of ADRs in PI and SI groups. Meta-analyses were performed for the most consistently reported ADRs between the groups.

Methods:

Objective

The primary objective for this meta-analysis was to determine the difference in incidence of ADRs in standard versus prolonged infusions of beta-lactams.

Search Strategy and Data Collection

To begin, all literature that was previously identified by the international consensus recommendations [24] under PICO question 7, "Is use of a prolonged-infusion beta-lactam safer than standard infusion in children" was considered. Then an updated literature search was completed using PubMed and included the following key search terms: "standard infusion," "extended infusion," "renal failure," "kidney damage," "kidney injury," "neurotoxicity," "beta-lactam," "cefepime," "piperacillin," "ceftriaxone." All articles were compiled after review of an inclusion/exclusion criteria in order to determine eligibility.

Inclusion/Exclusion Criteria:

To be eligible, studies were required to meet the following criteria: 1) randomized trials or non-randomized, prospective, or retrospective cohort studies; 2) ADRs reported; 3) beta-lactam usage either alone or in combination with other antibiotics consistent across both treatment arms; and 4) only 2 treatment arms (i.e., standard infusion and prolonged infusion). Studies were excluded for concomitant drug use varying amongst treatment arms, mixed use of standard infusion and prolonged infusion at the individual patient level, or not meeting inclusion criteria.

Data Extraction:

Pertinent data was entered into a data extraction table (Table 1). The data listed was collected for each individual study: studies characteristics (authors, publication year), patient population (age, disease state), treatment regimens (specific beta-lactam, infusion type), and ADRs within each group.

Data Analysis

Meta-analyses were performed for ADRs that occurred in 5 or more studies only. Statistics for the meta-analysis was performed using Review Manager V. 5.4 from Cochrane Library [25]. Fixed Odd-Ratios were calculated from the dichotomously reported ADR rates from each study with 95% Confidence Interval in RevMan [25]. Analysis and forest plot summary of the pooled adverse events were created in RevMan [25] (Figure 2 & 3). The quality of evidence and risk for bias was independently assessed by 3 study authors with majority rule for final classification. Analysis of study quality was performed via Newcastle-Ottawa Scale [26] (Table 3) and Cochrane Risk Bias [27] (Table 4) for retrospective and prospective studies, respectively. Publication bias was assessed visually using funnel plot inspection for nephrotoxicity (Figure 4) and diarrhea (Figure 5).

Results:

After initial screening, a total of 26 studies were assessed for eligibility for meta-analysis based on title and abstract (Figure 1). Nephrotoxicity and diarrhea were the most prevalent reported ADRs according to the inclusion criteria for the meta-analysis. Out of the 26 studies, 12 were excluded because no ADRs were reported (Figure 1). One study was excluded due to insufficient adverse events recording (Figure 1). After exclusion, a total of seven randomized control trials and six retrospective studies met inclusion criteria with data for 4196 patients. Eight studies reported nephrotoxicity from a total of 3564 patients with no significant difference in patients of standard (n=436/2276, 19.8%) vs prolonged infusion (n=267/1288, 20.6%) of beta-lactams (OR=1.08, 95% Confidence Interval [0.91, 1.29]) (Figure 2). Among the eight studies, five of them reported concomitant administration of vancomycin, 4 reported the exact number of patients receiving it. The total number of patients receiving concomitant vancomycin in these studies was 80.3%. Seven studies observed diarrhea in a total of 794 patients with no significant difference in patients of standard (n=21/417, 5.0%) vs prolonged (n=25/377, 6.6%) infusion of beta-lactams (OR=1.30, 95% Confidence Interval [0.71,2.37]) (Figure 3). No publication bias was detected for either nephrotoxicity (Figure 4) or diarrhea (Figure 5).

Discussion:

Our review and meta-analysis did not identify a signal for differences in ADRs between prolonged and standard infusion schemes. Lack of a safety signal is an important finding, given that prolonged infusions are being increasingly used to improve efficacy. Thus, if future studies are to reach the same conclusion, the most efficacious infusion protocols can be used without additional safety concerns.

Beta-lactams are generally regarded as safe agents, associated with minimal adverse effects. Nephrotoxicity and diarrhea were the ADRs most commonly recorded by the studies in question and were thus studied via meta-analysis. Other ADRs including cytopenias, neurotoxicity, electrolyte imbalance, elevated liver function tests, and rash were reported inconsistently, and it was thus not possible to quantitatively analyze these ADRs. Nephrotoxicity was classified broadly and as reported by the individual study (Table 2), but no difference was found between infusion strategies when the studies were pooled categorically. In future work, standardizing classification schema to acceptable standards (e.g., KDIGO) will result in more meaningful comparison of ADRs across studies. A single

standard would help increase specificity. In the present analysis, while many of the studies reported nephrotoxicity, some used the Acute Kidney Injury Network (AKIN) criteria [28], others used the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) criteria [28], and one relied on independent nephrologist assessment. It is also important to note that kidney injury rates here of ~20% are very unlikely due to the beta-lactam and are probably more representative of the severity of illness of patients for which beta-lactams are required (i.e. infectious syndromes). Patients often had concomitant medications that are known nephrotoxins (e.g. vancomycin, aminoglycosides). We did not quantify these concomitant medications since they were not consistently reported in a manner that facilitated quantification.

Beta-lactam induced kidney injury can be separated into acute interstitial nephritis and direct cellular toxicity (e.g. acute tubular necrosis) with the former more common via an immune-mediated, dose-independent response. While the exact mechanism of drug induced acute interstitial nephritis has not entirely been elucidated, it is thought that the beta-lactam triggers an immune response by acting as a hapten, causing the drug to be immunogenic and subsequently upregulate immunoglobulins. These upregulated immunoglobulins result in an immune response mediated by CD8+ cytotoxic T-cells [29,30]. The destruction induced by these T-cells leads to tubular injury/acute kidney injury and ultimately renal failure in some cases [30]. Such a mechanism is thought to be dose and exposure independent. For certain beta-lactams such as imipenem, dose/exposure mediated events can occur and lead to cellular accumulation and mitochondrial stress; [31] however, in the case of imipenem, the addition of cilastatin is specifically used to prevent accumulation.

Diarrhea associated with beta-lactam usage is thought to be linked to drug concentration intensity and total time of therapy [10,12,32-36]. Diarrhea from antibiotics such as beta-lactams is multifactorial and can be caused by specific superinfection or more general gut microbiota dysbiosis. *Clostridioides difficile* infection is an example of superinfection, although the more common ‘antibiotic diarrhea’ is likely due to dysbiosis. We saw no difference between beta-lactam infusion strategies for any diarrhea reported.

Beta-lactam-induced neurotoxicity is proposed to be dose and exposure mediated [22,23,37,38].While it is less clear if maximal concentrations or total exposure drives the toxicity, administration of prolonged infusion beta-lactams which utilize lower or equal doses to standard intermittent infusions is hypothesized to result in less neurotoxicity [39,40]. Given that none of the studies comparing PI to SI antibiotics focused on sensitive methods

that could monitor neurological findings (e.g. prespecified EEG testing), and that neurotoxicity is not a commonly reported ADR in general, it was not surprising that neurotoxicity was infrequently documented. Other adverse effects attributed to beta-lactams include rash, hepatic injury, and electrolyte imbalance. However, none of these ADRs occurred with considerable frequency in either group or were not measured in some of the studies, thus there was not enough data to quantitatively analyze them.

Limitations to this work include the frequent underestimation of ADRs in retrospective studies. Additionally, studies with subjects receiving both standard and prolonged infusions have not been specifically designed to detect differences in safety. As such, future studies should specifically place a focus on analyzing toxicity outcomes in a standardized manner for each of these infusion methods. It is important to also note that our meta-analysis utilized a definition of study-reported nephrotoxicity rather than a common unified definition. It was not possible to reclassify patients because the data were not available to do so. The definitions of nephrotoxicity, as presented in the studies, had considerable variation, with some studies lacking a clear and consistent characterization. Additionally, some of the studies included patients receiving concomitant nephrotoxic medications that may present a confounding variable. Cotner et. al, a study from which 2390 patients were included in this analysis, was a large retrospective study of hospitalized patients [51]. Many patients analyzed in the study required additional treatment with various nephrotoxic non-beta-lactam medications such as vancomycin (frequently administered with piperacillin/tazobactam), aminoglycosides, and loop diuretics that contributed to higher nephrotoxicity rates [51]. Finally, the characterization of ADRs in the majority of these studies were done in a clinical manner and was often left to physician characterization. Such reporting is subjective in nature. For future comparative studies between prolonged and standard infusion beta-lactams, it would be beneficial to utilize a standardized criteria for the classification of ADRs. An example includes the Common Terminology Criteria for Adverse Events (CTCAE) which is employed by organizations such as the National Cancer Institute and the FDA for this purpose. By utilizing an accepted standard set of criteria, the collection and utilization of safety data can be significantly improved. This will also result in enhanced external use of safety data for future research endeavors. In the context of our study, the incorporation of standardized criteria in future studies will yield the higher quality data that is required for a more comprehensive evaluation of the safety profile of these infusion protocols.

Conclusion:

Based on the dosing scheme of the analyzed studies, prolonged and standard beta-lactam infusion schemes displayed ADRs at similar rates. The most prevalent ADRs included nephrotoxicity and diarrhea; however, no difference was seen between PI and SI infusion strategies. Other ADRs were reported, however, frequency was low and reporting inconsistent. Further studies should be specifically designed to analyze toxicity outcomes from each of the infusion methods.

Figures:

Figure 1.



Figure 1: PRSIMA 2020 Flow Diagram for research identification

Figure 2.



Figure 2: Forest plot of the adverse side reaction of nephrotoxicity from prolonged (PI) vs standard infusion (II) of beta-lactams

Figure 3.



Figure 3: Forest plot of the adverse side reaction of diarrhea from prolonged (PI) vs standard infusion (II) of beta-lactams

Figure 4.



Figure 4. Funnel plot of the adverse side reaction of nephrotoxicity from prolonged (PI) vs standard infusion (II) of beta-lactams

Figure 5.



Figure 5. Funnel plot of the adverse side reaction of diarrhea from prolonged (PI) vs standard infusion (II) of beta-lactams

Table 1.
Data Extraction Table

Study	Year	Total Patients	# of Subjects of EI	# of ADRs in EI	% of ADRs in EI	# of Subjects in SI	# of ADRs in Standard Infusion	% of ADRs in SI	Study Design
Bauer[8]	2013	132	83	25	30.1%	49	12	24.5%	Retrospective
Abdul-Aziz[9]	2016	140	70	0	0%	70	0	0%	RCT
Chytra[10]	2012	240	120	10	8.3%	120	12	10%	RCT
Grant[41]	2002	98	47	0	0%	51	0	0%	RCT
Bao[33]	2017	50	25	11	44%	25	16	64%	RCT
Fan[42]	2017	367	182	0	0%	185	0	0%	RCT
McCormick[43]	2015	200	100	9	9%	100	11	11%	Retrospective
Mousavi[44]	2017	272	136	45	32.9%	136	40	29.3%	Retrospective
Dulhunty[45]	2013	60	30	0	0%	30	0	0%	RCT
Nicolau[46]	2001	35	17	11	64.7%	10	9	70%	RCT
Contrina-Luque[47]	2016	78	40	0	0%	38	0	0%	RCT
Van Zanten[13]	2006	93	47	0	0%	46	0	0%	RCT
Shabaan[14]	2017	102	51	12	23.5%	51	29	56.9%	RCT
McNabb[36]	2001	35	17	9	52.9%	18	13	72.2%	RCT
Karino[48]	2016	320	160	52	32.5%	160	53	33.1%	Retrospective
Winstead[49]	2016	181	86	0	0%	95	0	0%	Retrospective
Knoderer[15*]	2017	50	50	0	0%	0	0	0%	Retrospective
Ram[16]	2018	91	47	3	6.4%	58	6	6.9%	RCT
Nichols[50]	2015	150	143	0	0%	7	0	0%	Retrospective
Cotner[51]	2017	2390	690	149	21.6%	1700	316	18.6%	Retrospective
Roberts[20]	2006	57	28	0	0%	29	0	0%	RCT

Schmees[52]	2016	113	61	0	0%	52	0	0%	Retrospective
Nichols[31]	2019	67	21	2	14.3%	46	3	6.5%	Retrospective
Lau[30]	2006	262	130	14	10.8%	132	16	12.1%	RCT
Padari[17]	2012	19	10	0	0%	9	0	0%	RCT
Monti[21]	2023	607	303	0	0%	304	0	0%	RCT

*** Insufficient adverse events recording**

Table 2.

Data Extraction Table

	Nephrotoxicity Criteria Used						
Study	**Serum Creatinine x2 baseline or greater**	**Serum creatinine increase of 0.3 mg/dL or greater**	**RIFLE Criteria**	**AKIN Criteria**	**Vancomycin Consensus Guideline**	**Nephrologist Assessment**	**Not described**
Bauer 2013						X	
Cotner 2017			X				
Karino 2016			X	X			
McCormick 2015	X						
McNabb 2001							X
Mousavi 2017			X	X			
Ram 2018	X						
Shabaan 2017		X					

Table 3

Cochranes Risk of bias summary, review of author's judgements about each risk of bias item for each included study

Study	**Sequence Generation**	**Allocation concealment**	**Blinding**	**Incomplete outcome**	**Selective Reporting**	**Other bias**	**Intention to treat**	**Sample calculation**
McNabb 2001	+	+	-	-	-	-	+	-
Ram 2018	+	+	-	-	-	-	+	+

Shabbaan 2017	+	+	+	-	-	-	+	+
Chytra 2012	+	+	-	-	-	-	+	+
Bao 2017	+	+	-	-	-	-	+	-
Nicolau 2001	+	+	-	-	-	-	+	-
Lau 2006	+	+	-	-	-	-	+	+

Legend:

+ Low Risk of Bias
– High Risk of Bias

Table 4

Risk of bias assessment using Newcastle-Ottawa Score

Study	D1	D2	D3	D4	D5	Overall
Bauer 2013	+	+	+	+	+	+
McCormick 2015	+	+	+	+	+	+
Mousavi 2017	+	+	+	+	+	+
Karino 2016	-	+	+	+	+	-
Nichols 2015	+	+	+	+	+	+
Cotner 2017	+	+	+	+	+	+

Domains:

D1: Bias arising from the randomization process
D2: Bias due to deviations from intended intervention
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in the selection of the reported result.

Judgment:

+ Low Concern
- Some Concern
x High Concern

References:

1. Magil S, O'Leary, E., Kainer, M. et al. Comparison of Results From Emerging Infections Program Prevalence Surveys, 2015 and 2011. *Clin Infect Dis*. 2021;72(10):1784-1792. doi:10.1093/cid/ciaa373
2. Browne AJ, Chipeta, M.G., Haines-Woodhouse, G et al. Global antibiotic consumption and usage in humans, 2000–18: a spatial modeling study. *The Lancet Planetary Health*. 2021;5(12):893-904. doi:10.1016/S2542-5196(21)00280-1
3. Amoah J, Klein, E., Cosgrove, S. et al. Administration of a β-Lactam Prior to Vancomycin as the First Dose of Antibiotic Therapy Improves Survival in Patients With Bloodstream Infections. *Clin Infect Dis*. 2022;75(1):98-104. doi:10.1093/cid/ciab865
4. Thakuria BL, K. The Beta Lactam Antibiotics as an Empirical Therapy in a Developing Country: An Update on Their Current Status and Recommendations to Counter the Resistance against Them. *J Clin Diagn Res*. 2013;7(6):1207-1214. doi:10.7860/JCDR/2013/5239.3052
5. Moehring RS, C. *Prolonged infusions of beta-lactam antibiotics*. UpToDate; 2021.
6. Guilhaumou R, Benabound, S. and Bennis, Y. et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and I. *Crit Care*. 2019;23(104)doi:10.1186/s13054-019-2378-9
7. Ammar M, & Abdalla, W. . Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia. *Saudi J Anaesth*. 2018;12(1):89-94. doi:10.4103/sja.SJA_148_17
8. Bauer KA, Gentene, A.J., West, J.E. et al. n Antimicrobial Stewardship Program's Evaluation of the Safety and Efficacy of Continuous Infusion of Nafcillin in the Treatment of Methicillin-Sensitive Staphylococcus aureus Bacteremia. *Infectious Diseases in Clinical Practice*. 2013;21(2):111-113. doi:10.1097/IPC.0b013e318278f539
9. Abdul-Aziz M, Sulaiman, H., Mat-Nor, M., et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labeled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. *Intensive Care Med*. 2016;42(10):1535-1545. doi:10.1007/s00134-015-4188-0
10. Chytra I, Stepan, M., Benes, J., et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. *Critical Care*. 2012;16(3):113. doi:10.1186/cc11405
11. Dullhunty J, Roberts, J., & Davis, J. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. *Clin Infect Dis*. 2013;56(2):236-244. doi:10.1093/cid/cis856
12. Nicolau D, McNabb, J., Quinitiliani, R., et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. *Int J Antimicrob Agents*. 2001;17(6):497-504. doi:10.1016/s0924-8579(01)00329-6
13. Van Zanten A, Oudijk, M., Nohlmans-Paulssen, M., et al. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. *Br J Clin Pharmacol*. 2007;63(1):100-109. doi:10.1111/j.1365-2125.2006.02730.x
14. Shabaan A, Elsayed Eldegla, H., Nasef, N., et al. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial. *Pediatr Infect Dis J*. 2017;36(4):363-368. doi:10.1097/INF.0000000000001445
15. Knoderer C, Karmire, L. Andricopulos, K., et al. Extended Infusion of Piperacillin/Tazobactam in Children. *J Pediatr Pharmacol Ther*. 2017;22(3):212-217. doi:10.5863/1551-6776-22.3.212nichols
16. Ram R, Halavy., Paran, Y., et al. Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial. *Clin Infect Dis*. 2018;67(8):1153-1160. doi:10.1093/cid/ciy258
17. Padari H, Metsvaht, T., Kõrgvee, L., et al. Short versus long infusion of meropenem in very-low-birth-weight neonate. *Antimicro Agents Chemother*. 2012;56(9):4760-4764. doi:10.1128/AAC.00655-12
18. Kondo Y, Ota, K. Imura, H., et al. Prolonged versus intermittent β-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients: a systematic review with meta-analysis and trial sequential analysis of launichrandomized trial. *J Intensive Care*. 2020;8(77)doi:10.1186/s40560-020-00490-z
19. Vardakas K. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. *Lancet Infect Dis*. 2017;18(1):108-120. doi:10.1016/S1473-3099(17)30615-1
20. Roberts JA, Abdul-Aziz, M-H., Davis, J., et al. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. *Am J Respir Crit Care Med*. 2016;194(6):681-691. doi:10.1164/rccm.201601-0024OC

21. Monti G, Bradić N, Marzaroli M, et al. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial. *JAMA*. 2023;330(2):141–151. doi:10.1001/jama.2023.10598

22. Roger, C., & Louart, B. (2021). Beta-lactams toxicity in the intensive care unit: An underestimated collateral damage? *Microorganisms*, *9*(7), 1505. https://doi.org/10.3390/microorganisms9071505

23. Barreto EF, Webb AJ, Pais GM, Rule AD, Jannetto PJ, Scheetz MH. Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling? Crit Care Explor. 2021 Jun 11;3(6):e0446. doi: 10.1097/CCE.0000000000000446. PMID: 34136822; PMCID: PMC8202642.

24. Hong, L. T., Downes, K. J., FakhriRavari, A., Abdul-Mutakabbir, J. C., Kuti, J. L., Jorgensen, S., Young, D. C., Alshaer, M. H., Bassetti, M., Bonomo, R. A., Gilchrist, M., Jang, S. M., Lodise, T., Roberts, J. A., Tängdén, T., Zuppa, A., & Scheetz, M. H. (2023). International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy, 43(8), 740–777. https://doi.org/10.1002/phar.2842

25. Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020.

26. Gierisch JM, Beadles C, Shapiro A, et al. Health Disparities in Quality Indicators of Healthcare Among Adults with Mental Illness [Internet]. Washington (DC): Department of Veterans Affairs (US); 2014 Oct. APPENDIX B, NEWCASTLE-OTTAWA SCALE CODING MANUAL FOR COHORT STUDIES.

27. Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A., Cochrane Bias Methods Group, & Cochrane Statistical Methods Group (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed.)*, *343*, d5928. https://doi.org/10.1136/bmj.d5928

28. Bellomo R, Ronco C, Kellum JA, et al. Palevsky P and the ADQI workgroup. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care*. 2004;8:R204. doi:10.1016/S1470-2045(07)70246-2.

29. Bluementhal K, Peter, J., & Phillips E. Antibiotic Allergy. *Lancet*. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9

30. Spanou Z, Keller, M., Yawalkar, N., et al. Involvement of Drug-Specific T Cells in Acute Drug-Induced Interstitial Nephritis. *Clin J Am Soc Nephrol*. 2006;17(10):2919-2927. doi:10.1681/ASN.2006050418

31. Tune, B.M. Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention. *Pediatr Nephrol* 11, 768–772 (1997). https://doi.org/10.1007/s004670050386

32. Barbut F, & Meynard, J. . Managing antibiotic associated diarrhoe. *BMJ*. 2002;324(7450):1345-1346. doi:10.1136/bmj.324.7350

33. Bao H, Wang, D., Xue, J., et al. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial. *Eur J Clin Microbiol Infect Dis*. 2017;36:459-466. doi:10.1007/s10096-016-2819-1

34. Lau W, Mercer, D., Itani, Kamal., et al. Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection. *Antimicro Agents Chemother*. 2006;50(11):3556-3561. doi:10.1128/AAC00329-06

35. Nichols K, Beauchamp, L., & Knoderer C. Outcomes of Extended Infusion Cefepime in Pediatric Patients. *Infect Dis Clin Pract*. 2019;27:283-287.

36. McNabb J, Nightingale, C., Quintillani, R., et al. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. *Pharmacotherapy*. 2001;21(5):549-555. doi:10.1592/phco.21.6.549.34539

37. Silvia E. Schliamser, Otto Cars, S. Ragnar Norrby, Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis, *Journal of Antimicrobial Chemotherapy*, Volume 27, Issue 4, April 1991, Pages 405–425, https://doi.org/10.1093/jac/27.4.405

38. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011 Sep;72(3):381-93. doi: 10.1111/j.1365-2125.2011.03991.x. PMID: 21501212; PMCID: PMC3175508.

39. Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. *Crit Care*. 2017;21(1):276. Published 2017 Nov 14. doi:10.1186/s13054-017-1856-1

40. Al-Shaer, M. H., & Peloquin, C. A. (2021). Using precision dosing to minimize cefepime-induced neurotoxicity: The challenge of targets. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*, *27*(6), 929–930. https://doi.org/10.1016/j.jiac.2021.02.020

41. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002;22:471-83.

42. Fan SY, Shum HP, Cheng WY, Chan YH, Leung SM, Yan WW. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial. Pharmacotherapy 2017;37:109-19.

43. McCormick H, Tomaka N, Baggett S, et al. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam. Am J Health Syst Pharm 2015;72:S25-30.

44. Mousavi M, Zapolskaya T, Scipione MR, Louie E, Papadopoulos J, Dubrovskaya Y. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion. Pharmacotherapy 2017;37:379-85.

45. Dulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A., Bellomo, R., Gomersall, C., Shirwadkar, C., Eastwood, G. M., Myburgh, J., Paterson, D. L., & Lipman, J. (2013). Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, *56*(2), 236–244. https://doi.org/10.1093/cid/cis856

46. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001;17:497-504.

47. Cotrina-Luque J, Gil-Navarro MV, Acosta-Garcia H, et al. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa. International Journal of Clinical Pharmacy 2016;38:70-9.

48. Karino S, Kaye KS, Navalkele B, et al. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship. Antimicrob Agents Chemother 2016;60:3743-50.

49. Winstead EM, Ratliff PD, Hickson RP, Mueller JE, Judd WR. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections. Int J Clin Pharm 2016;38:1087-93.

50. Nichols KR, Karmire LC, Cox EG, Kays MB, Knoderer CA. Implementing extended-infusion cefepime as standard of care in a children's hospital: a prospective descriptive study. Ann Pharmacother 2015;49:419-26.

51. Cotner S, Rutter WC, Burgess DR, Martin C, Burgess DS. Influence of beta-lactam infusion strategy on acute kidney injury. Open Forum Infectious Diseases 2016;3.

52. Schmees PM, Bergman SJ, Strader BD, Metzke ME, Pointer S, Valenti KM. Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit. Am J Health Syst Pharm 2016;73:S100-5.